Table 1.
Honey | Aqueous cream | Honey minus cream | p | |
---|---|---|---|---|
Acceptability | ||||
Score (0–100) | 71.1 (27.6) | – | – | – |
Clinical outcomes | ||||
Intensity (0–12) | ||||
V1 | 4.2 (1.5) | 4.0 (1.4) | ||
V2 | 2.9 (1.4) | 3.2 (1.5) | −0.3 (1.2) | 0.61* |
Change with treatment | −1.3 (1.0) | −0.8 (1.5) | −0.5 (1.5) | 0.25* |
Severity (0–100) | ||||
V1 | 49.3 (25.9) | 49.1 (23.6) | ||
V2 | 32.1 (27.6) | 36.9 (28.2) | −4.8 (−13 to 3.7)† | 0.25‡ |
Change with treatment | −17.2 (16.8) | −12.2 (10.8) | −5.0 (−14.3 to 4.4)† | 0.27‡ |
Adherence | ||||
Duration of use (min) | 565.8 (76.7) | 563.0 (76.1) | – | – |
Values reported as mean (SD) unless otherwise stated. For Psoriasis Area and Severity Index intensity scores, higher scores represent more severe disease. Acceptability scores range from 0 ‘completely unacceptable’ to 100 ‘completely acceptable’. Severity scores range from 0 ‘mildest possible’ to 100 ‘Worst possible’. V1: Baseline visit 1; V2: Visit 2 after two weeks’ treatment.
Signed rank tests.
Mean (95% confidence interval).
Paired t-test.